Ristova (Rituximab) is a monoclonal antibody designed to target the CD20 protein found on the surface of B-lymphocytes. By binding to these cells, it helps in their destruction, making it an effective treatment for blood cancers such as non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as autoimmune diseases like rheumatoid arthritis.
Key Features:
Active Ingredient: Rituximab
Strength: 100mg/10ml
Form: Concentrate for solution for infusion
Manufacturer: Roche
Indications:
Ristova is commonly prescribed for the treatment of:
- Non-Hodgkin’s lymphoma (NHL)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis (in combination with methotrexate)
- Granulomatosis with polyangiitis and microscopic polyangiitis
Administration and Dosage:
Administered via intravenous infusion under medical supervision. The dosage and infusion rate may vary based on the condition being treated and the patient’s response to therapy. Premedication with antihistamines and corticosteroids is often recommended to reduce infusion-related reactions.
Storage Instructions:
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep in the original packaging.
Precautions:
Monitor for infusion-related reactions, infections, and possible reactivation of hepatitis B virus. Patients should be closely monitored for tumor lysis syndrome and progressive multifocal leukoencephalopathy (PML). Not recommended during pregnancy or breastfeeding.
Note: This is a prescription-only medication and should be used under the guidance of a healthcare professional.
Reviews
There are no reviews yet.